Prognostic value and clinicopathological roles of the tumor immune microenvironment in salivary duct carcinoma
Hideaki Hirai,Masato Nakaguro,Yuichiro Tada,Natsuki Saigusa,Daisuke Kawakita,Yoshitaka Honma,Satoshi Kano,Kiyoaki Tsukahara,Hiroyuki Ozawa,Takuro Okada,Kenji Okami,Keisuke Yamazaki,Yukiko Sato,Makoto Urano,Manami Kajiwara,Yoshitaka Utsumi,Tomotaka Shimura,Chihiro Fushimi,Akira Shimizu,Takahito Kondo,Yorihisa Imanishi,Akihiro Sakai,Yuichiro Sato,Takafumi Togashi,Toyoyuki Hanazawa,Takashi Matsuki,Kazuto Yamazaki,Toshitaka Nagao
DOI: https://doi.org/10.1007/s00428-023-03598-3
Abstract:Salivary duct carcinoma (SDC) is an aggressive type of salivary gland carcinoma. Recently, immunotherapies targeting immune checkpoints, including PD1, PD-L1, CTLA4, and LAG3, have had a considerable prognostic impact on various malignant tumors. The implementation of such immune checkpoint inhibitor (ICI) therapies has also been attempted in cases of salivary gland carcinoma. The tumor immune microenvironment (TIME) is implicated in tumorigenesis and tumor progression and is closely associated with the response to ICI therapies. However, the TIME in SDC has not been fully explored. We examined the immunohistochemical expression of CD8, FOXP3, PD1, PD-L1, CTLA4, LAG3, and mismatch repair (MMR) proteins, tumor-infiltrating lymphocytes (TILs), and microsatellite instability (MSI) status in 175 cases of SDC. The associations between these TIME-related markers and the clinicopathological factors and prognosis were evaluated. An elevated expression of CD8, FOXP3, PD1, CTLA4, and LAG3 was associated with more aggressive histological features and an advanced N and/or M classification, elevated Ki-67 index, and poor prognosis. Furthermore, cases with a high PD-L1 expression exhibited more aggressive histological features and adverse clinical outcomes than those with a low expression. Alternatively, there was no significant correlation between TILs and clinicopathological factors. No SDC cases with an MSI-high status or MMR deficiency were found. The coexistence of both an immunostimulatory and immunosuppressive TIME in aggressive SDC might play a role in the presence of T-cell exhaustion. The contribution of multiple immune escape pathways, including regulatory T cells and immune checkpoints, may provide a rationale for ICI therapy, including combined PD1/CTLA4 blockade therapy.